Cover Image
市場調查報告書

頭孢菌素劑的市全球場:趨勢,市場分析(2017 - 2022年)

Global Cephalosporin Drugs Market - Trends, Market Analysis - (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 391378
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
頭孢菌素劑的市全球場:趨勢,市場分析(2017 - 2022年) Global Cephalosporin Drugs Market - Trends, Market Analysis - (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

頭孢菌素是一組衍生自頭孢黴屬的廣效、半合成β-內醯胺抗生素。對於少數適應症,頭孢菌素是首選抗生素。這個市場成長的關鍵驅動力是許多國家的研究和開發活動增加以及對抗菌素的需求不斷成長。預計市場將經歷不確定的監管改革,研發成本高昂,並不預期的投資回報。還有這類抗菌藥物的管道藥物開發較少。

本報告提供全球頭孢菌素劑市場調查,整體市場趨勢,產品、各地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 數量單位
  • 基本貨幣
  • 檢討與預測期間
  • 調查的一般前提條件

第2章 調查方法

  • 簡介
  • 分析方法論
  • 計量經濟學的預測模式
  • 調查的前提條件

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 頭孢菌素概要
    • 化學結構
    • 其他地區動的結構
    • 流行病學
    • 有害的影響
    • 治療上的用途
    • 投藥數量
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 研究開發投資的增加
    • 抗菌劑需求高漲
    • 疾病的流行的擴大
  • 市場阻礙因素
    • 不確實的法規改革
    • 低的投資回報率
    • 在開發平台的藥物的削減

第7章 全球頭孢菌素劑市場:各譜系

  • 第1代
  • 第2代
  • 第3代
  • 第4代
  • 第5代

第8章 全球頭孢菌素劑市場:各給藥途徑

  • 口服
  • 注射劑

第9章 全球頭孢菌素劑市場:各類型

  • 品牌
  • 非專利的

第10章 全球頭孢菌素劑市場:各治療類型

  • 治療的最前線
    • 性感染疾病
    • 嚴重的感染疾病
  • 治療的第二線
    • 呼吸系統感染疾病
    • 皮膚感染疾病
    • 妊娠中的泌尿道感染

第11章 全球頭孢菌素劑市場:法規環境

第12章 全球頭孢菌素劑市場:各地區佔有率與預測

  • 北美(NA)
    • 簡介
    • 南北美洲
    • 加拿大
    • 其他
  • 歐洲
    • 簡介
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區(APAC)
    • 簡介
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 中東、非洲地區(MEA)
    • 簡介
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 中南美
    • 簡介
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他

第13章 競爭情形

  • M&A分析
  • 競爭對手

第14章 主要供應商分析

  • Astellas
  • Lupin Pharmaceuticals
  • Bristol-Myers Squibb
  • Glaxo SmithKline
  • Roche
  • Ranbaxy
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

第15章 分析師的投資機會預測

第16章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The Global Cephalosporin Drugs Market is estimated to be $ xx billion for the year 2015 to reach $ xx billion by the year 2020. The CAGR with which market is growing is anticipated to be x.x%.

The cephalosporins are a group of broad spectrum, semi-synthetic beta-lactam antibiotics derived from the group Cephalosporium. For few indications, cephalosporins are the preferred anti antibiotics. The key driver for the growth of this market is increasing research and development activities in many countries and the growing demand of anti-bacterials. The market is expected to experience uncertain regulatory reforms and spending high in research and development does not fetch the expected return of investment. It has also been observed that there is less drug development in pipeline for this category of anti-bacterials.

The global cephalosporin drugs market is segmented based on the spectrum of anti-microbial activity which includes first generation, second generation, third generation, fourth generation and fifth generation. The market is also segmented by the route of administration such as oral and injectables, by type such as branded and generics. The therapeutic segment of the market includes sexually transmitted infections, serious infections, respiratory tract infections, skin infections, urinary tract infections in pregnancy. The geographical regions considered include North America, Europe, Latin America, Middle East Asia and Asia Pacific. The clinical trial support services regulations differs from region to region.

The major companies in this market are Astellas, Lupin Pharmaceuticals, Bristol-Myers Squibb, Glaxo SmithKline, Roche, Ranbaxy, Merck, Pfizer, Sandoz,Teva Pharmaceuticals.

This report offers comprehensive profiles of these companies composed of their business strategy for biosimilars, financials, SWOT analysis, products and services and the insightful company analysis by our analyst.

What the report offers

Market Definition for the specified topic along with identification of key drivers and restraints for the market.

Market analysis for the Global Cephalosporin Drugs Market, with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the Macro and Micro factors that affect the Global Biosimilars market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Table of Contents

1. Introduction

  • 1.1 Study Deliverables
  • 1.2 Market Definition
  • 1.3 Sizing Units
  • 1.4 Base Currency
  • 1.5 Review and Forecast Period Years
  • 1.6 General Study Assumptions

2. Research Methodology

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Econometric Forecast Model
  • 2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

  • 5.1 Current Market Scenario
  • 5.2 Cephalosporins Overview
    • 5.2.1 Chemical Structure
    • 5.2.2 Mechanism of Action
    • 5.2.3 Epidemiology
    • 5.2.4 Adverse Effects
    • 5.2.5 Therapeutic Uses
    • 5.2.6 Dosage
  • 5.3 Porter's Five Forces
    • 5.3.1 Bargaining Power of Suppliers
    • 5.3.2 Bargaining Power of Consumers
    • 5.3.3 Threat of New Entrants
    • 5.3.4 Threat of Substitute Products and Services
    • 5.3.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increasing R&D Investments
    • 6.1.2 Growing demand for the antibacterials
    • 6.1.3 Increasing Prevalence of Diseases
  • 6.2 Market Restraints
    • 6.2.1 Uncertain regulatory reforms
    • 6.2.2 Low return of investment
    • 6.2.3 Less drugs in pipeline

7. Global Cephalosporin Drugs Market, by Spectrum

  • 7.1 First Generation
  • 7.2 Second Generation
  • 7.3 Third Generation
  • 7.4 Fourth Generation
  • 7.5 Fifth Generation

8. Global Cephalosporin Drugs Market, by Route of Administration

  • 8.1 Oral
  • 8.2 Injectables

9. Global Cephalosporin Drugs Market, by Type

  • 9.1 Branded
  • 9.2 Generics

10. Global Cephalosporin Drugs Market, by Type of Treatment

  • 10.1 First Line of Treatment
    • 10.1.1 Sexually transmitted infections
      • 10.1.1.1 Gonorrhoea
      • 10.1.1.2 Pelvic inflammatory disease
      • 10.1.1.3 Epididymo-orchitis
    • 10.1.2 Serious infections
      • 10.1.2.1 Meningitis
  • 10.2 Second Line of Treatment
    • 10.2.1 Respiratory tract infections
      • 10.2.1.1 Otitis media
      • 10.2.1.2 Sinusitis
    • 10.2.2 Skin infections
      • 10.2.2.1 Cellulitis
      • 10.2.2.2 Diabetic foot infections
      • 10.2.2.3 Mastitis
    • 10.2.3 Urinary tract infections in pregnancy

11. Global Cephalosporin Drugs Market, Regulatory Landscape

12. Global Cephalosporin Drugs Market, by Geography - Regional Share and Forecasts

  • 12.1 North America (NA)
    • 12.1.1 Introduction
    • 12.1.2 United States
    • 12.1.3 Canada
    • 12.1.4 Rest of North America
  • 12.2 Europe
    • 12.2.1 Introduction
    • 12.2.2 Germany
    • 12.2.3 United Kingdom
    • 12.2.4 France
    • 12.2.5 Italy
    • 12.2.6 Spain
    • 12.2.7 Russia
    • 12.2.8 Rest of the Europe
  • 12.3 Asia-Pacific (APAC)
    • 12.3.1 Introduction
    • 12.3.2 China
    • 12.3.3 Japan
    • 12.3.4 India
    • 12.3.5 Australia
    • 12.3.6 South Korea
    • 12.3.7 Rest of Asia-Pacific
  • 12.4 Middle-East and Africa (MEA)
    • 12.4.1 Introduction
    • 12.4.2 UAE
    • 12.4.3 Saudi Arabia
    • 12.6.4 Israel
    • 12.6.5 Rest of the MEA
  • 12.5 Latin America
    • 12.6.1 Introduction
    • 12.6.2 Brazil
    • 12.6.3 Argentina
    • 12.6.4 Mexico
    • 12.6.5 Rest of Latin America

13. Competitive Landscape

  • 13.1 Merger and Acquisition Analysis
  • 13.2 The Challengers

14. Key Vendor Analysis

  • 14.1 Astellas
  • 14.2 Lupin Pharmaceuticals
  • 14.3 Bristol-Myers Squibb
  • 14.4 Glaxo SmithKline
  • 14.5 Roche
  • 14.6 Ranbaxy
  • 14.7 Merck
  • 14.8 Pfizer
  • 14.9 Sandoz
  • 14.10 Teva Pharmaceuticals

15. Analyst Outlook for Investment Opportunities

16. Future Outlook of the Market

Back to Top